Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06312-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Kun Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zigong First People's Hospital, Zigong, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Triazoles, Hydrazines, fms-Like Tyrosine Kinase 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine. To our knowledge, this is the first report demonstrating the effectiveness of this combination therapy for relapsed/refractory NUP98-NSD1+/FLT3-ITD + AML. This report highlights the potential synergy between selinexor and established AML therapies, suggesting a promising approach to improve outcomes for refractory AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zigong First People's Hospital, Zigong, China.
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, Guangxi, China.
- Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, Guangxi, China. yin-xl@163.com.
Zitieren
APA
Yang, K., Yang, B., Zhou, Y., Huang, Q., & Yin, X. (2025). Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06312-2
Vancouver
Yang K, Yang B, Zhou Y, Huang Q, Yin X. Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06312-2
BibTeX
@article{Yang2025,
author = {Yang, Kun and Yang, Beibei and Zhou, Yali and Huang, Qiuying and Yin, Xiaolin},
title = {Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06312-2}
}
EUVIMED